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redictive Factors for Ischemic Target Vessel
evascularization in the Prevention of Restenosis
ith Tranilast and its Outcomes (PRESTO) Trial
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alon K. L. Ho, MD, MSC,‡ James T. Willerson, MD,§ William F. Penny, MD,
avid R. Holmes, JR, MD*
ochester, Minnesota; Boston, Massachusetts; Houston, Texas; and San Diego, California
OBJECTIVES The aim of the present study was to determine the rates of target vessel revascularization
(TVR) and to determine predictors of TVR from clinical and angiographic variables available
in the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) database.
BACKGROUND The rates of TVR after percutaneous revascularization procedures, and its prediction with
available clinical and angiographic variables, is less well known.
METHODS We studied nine-month TVR in 11,484 patients enrolled in the PRESTO trial. Clinical,
lesion-related, and procedural characteristics were analyzed in a logistic regression model.
Study data were divided at random into an 80% training set on which the models were
developed and a 20% hold-out set on which the model properties were evaluated.
RESULTS A total of 14% (n 1,609) had ischemic TVR. Clinical variables with increased risk for TVR
included younger age; hypertension; diabetes mellitus; nonsmokers; unstable angina; previous
coronary artery bypass grafting; peripheral vascular disease; procedure- and lesion-related
such as ostial location, multilesion angioplasty, location in the left anterior descending artery,
length 20 mm, in-stent restenosis at baseline, and use of rotablator. There was significant
increase in the risk of ischemic TVR at U.S. treatment sites. Smoking and stent placement
were associated with lower risk of ischemic TVR. The mean area ( SD) under the
receiver-operating characteristic curve of the bootstrap samples was 0.66, indicating a modest
ability of the model to discriminate patients who needed TVR on follow-up.
CONCLUSIONS Despite being the largest prospective trial designed to test restenosis, the discriminatory
ability of the clinical and angiographic variables to predict TVR is modest. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.05.089Cardiol 2005;45:198–203) © 2005 by the American College of Cardiology Foundation
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Srevious clinical and angiographic studies of percutaneous
oronary interventions (PCI) have consistently observed
isparity in clinical and angiographic rates of restenosis,
ith higher rates of angiographic restenosis (1–4). Though
ngiographic assessment of restenosis helps in identifying
he clinical and angiographic variables in its causation, the
rue measure of success or failure after PCI is determined,
owever, by the clinical events such as death, myocardial
nfarction, and target vessel revascularization (TVR) (1). In
ddition, derivation of information from pooled informa-
ion from different trials and registries and inclusion of
elected populations limits the generalizability of the results.
he Prevention of Restenosis With Tranilast and its Out-
omes (PRESTO) trial was designed to evaluate the effects
f tranilast, an oral anti-inflammatory agent, on major
dverse cardiovascular events and angiographic and intra-
ascular end points (5). The PRESTO trial provided
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Harvard Clinical Research Institute, Boston, Massachusetts; §Texas Heart Institute,
ouston, Texas; and the University of California, San Diego, California. David J.
oliterno acted as guest editor on this article.n
Manuscript received March 25, 2004; revised manuscript received May 10, 2004,
ccepted May 11, 2004.mportant information on ischemic TVR in 11,484 patients.
ith this background, we sought to study the rates of
schemia-related TVR in the current interventional era. The
econd purpose of this retrospective analysis was to identify
nd predict the clinical and angiographic variables that
ncrease the risk of ischemic TVR and to internally validate
he predictors in the PRESTO trial.
ETHODS
tudy population. The PRESTO trial has been previously
escribed (5). In brief, it was a double blind, placebo-
ontrolled, parallel group study of patients after PCI. The
rimary end point was the first occurrence of major adverse
ardiovascular events within nine months defined as death,
yocardial infarction, and/or ischemia-driven TVR. Reste-
osis was defined as 50% stenosis in the treated segment
t follow-up, or at least 50% loss of the original gain in the
inimal luminal diameter. Ischemia-driven TVR was de-
ned as intervention for chest pain or a positive test for
schemia (exercise stress test, stress echocardiogram, 24-h
olter monitor, resting electrocardiographic evidence of
T-segment depression or elevation in 1 lead, or radio-
uclide study showing reversible defect). The type of inter-
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he exclusion of intracoronary radiation.
tatistical analysis. Summary data are expressed as the
ean value  SD or as a percentage. Unadjusted compar-
sons between those who developed ischemic TVR within
ine months and those who did not were performed with
hi-square tests for categorical patient or lesion character-
stics, and two-sample t tests for continuous variables.
aseline demographic, patient characteristics, angiographic,
nd procedural variables were screened univariately using a
0.05 level of significance. Standard stepwise procedures
ere then used to select variables to include in the final
ultivariable model. A two-tailed p value 0.05 was
onsidered significant. A multiple logistic regression model
as constructed with the following variables considered as
andidates: age, Caucasian race, study center, gender, hy-
ertension, treated diabetes mellitus (oral agent or insulin),
moking status, previous coronary artery bypass surgery,
revious PCI, dyslipidemia, history of congestive heart
ailure, current unstable angina, peripheral vascular disease,
merican College of Cardiology/American Heart Associa-
Abbreviations and Acronyms
PCI  percutaneous coronary intervention
PRESTO  Prevention of Restenosis With Tranilast
and its Outcomes trial
ROC  receiver-operating characteristic
TVR  target vessel revascularization
Table 1. Baseline Clinical Characteristics of Pa
Age (yrs)
Male, n (%)
Tranilast treatment, n (%)
Treatment center, n (%)
United Kingdom, West Europe, South Africa
U.S.
Other
Medical history, n (%)
Current smoker
Hypertension
Diabetes mellitus
Dyslipidemia
Previous myocardial infarction
Previous coronary bypass surgery
Previous percutaneous interventions
History of congestive heart failure
History of coronary artery disease
History of acute coronary syndrome
Peripheral vascular disease
Cerebrovascular accidents
History of stable angina
Previous unstable angina
Current stable angina
Current unstable angina
StatinsTVR  target vessel revascularization.ion type C lesion, and lesion characteristics ([length 20
m], bifurcation, ostial, in-stent restenosis, restenotic, dif-
use, discrete, pre-PCI stenosis, use of intracoronary stent,
otablator, vessel treated [left anterior descending vs. oth-
rs], lesions treated [single vs. multiple]).
The model’s goodness-of-fit was assessed using the
osmer-Lemeshow method. Model discrimination was
ssessed using the area under the receiver-operating char-
cteristic (ROC) curve or the c-statistic. Study data were
ivided at random into an 80% training set on which the
odels were developed, and a 20% hold-out set on which
he model properties such as the area under the ROC curve
ere evaluated. The risk score was calculated for each
atient and the area under the ROC curve was determined
or each sample. To study the performance of the variables on
atient subgroups, the data were stratified according to de novo
esions and adjusted for whether they received the stent.
ESULTS
aseline characteristics. A total of 11,484 patients were
nrolled in the PRESTO trial. Ischemia-driven TVR was
oted in 1,609 patients (14%). The baseline characteristics
f patients who required ischemic TVR and those who did
ot (n  9,875) are shown in Table 1. Among other
haracteristics, female gender, nonsmoker, hypertension,
reated diabetes mellitus, hyperlipidemia, history of percu-
aneous or surgical revascularization, congestive heart fail-
re, acute coronary syndrome, and peripheral vascular dis-
ase were associated with higher incidence of ischemic TVR.
s With and Without TVR
VR Event
 1,609)
No TVR Event
(n  9,875) p Value
9.9  10.5 60.3 10.4 0.21
,200 (75) 7,693 (78) 0.003
,285 (80) 7,901 (80) 0.89
 0.001
534 (33) 4,321 (44)
929 (58) 4,097 (42)
141 (9) 1,401 (14)
297 (18) 2,299 (23)  0.001
,107 (69) 5,904 (60)  0.001
480 (30) 2,204 (22)  0.001
,103 (69) 6,343 (64)  0.001
625 (39) 3,828 (39) 0.94
313 (19) 1,248 (13)  0.001
707 (44) 2,844 (29)  0.001
127 (8) 569 (6)  0.001
975 (61) 5,407 (55)  0.001
,115 (69) 5,680 (58)  0.001
131 (8) 548 (6)  0.001
68 (4) 315 (3) 0.031
334 (21) 1,532 (16)  0.001
603 (38) 2,873 (29)  0.001
571 (35) 4,154 (42)  0.001
988 (62) 4,898 (50)  0.001
,264 (79) 7,128 (72)  0.001tient
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ith and without ischemic TVR. Longer lesion length
20 mm), tighter preprocedure stenosis, higher residual
tenosis, and use of rotablator were associated with higher
ncidence of ischemic TVR. The lesion characteristics
ssociated with higher TVR were bifurcation, ostial, diffuse,
estenotic lesions, or lesions with in-stent restenosis.
ultivariable correlates. Stepwise regression modeling
esults of the variables associated with significantly increased
isk of ischemic TVR are presented in Table 3. The
ignificant independent predictors of TVR in this study are
ge, treatment site (U.S.), nonsmoker, hypertension, treated
iabetes mellitus, peripheral vascular disease, previous cor-
nary artery bypass surgery, and current unstable angina.
mong the angiographic predictors, lesion length20 mm,
stial location, angioplasty of left anterior descending artery,
ultivessel angioplasty, and use of rotablator were associ-
ted with a higher incidence of ischemic TVR. The data did
ot deviate significantly from the logistic model, as indi-
Table 2. Lesion Characteristics of Patients Wi
TVR Eve
(n  1,60
Lesion length, n (%)
10 mm 422 (2
10–20 mm 909 (5
20 mm 260 (1
Pre-PCI stenosis 88.2 9.
Post-PCI stenosis 6.7 11
PCI procedure, n (%)
Balloon dilation 1,596 (9
Rotablator 137 (9
Stent 1,120 (7
Lesion characteristics, n (%)
Angulated 45° 130 (8
Bifurcated 191 (1
Calcified 255 (1
De novo 1,188 (7
Diffuse disease 406 (2
Discrete 376 (2
Eccentric 769 (4
In-stent restenosis 361 (2
Irregular 418 (2
Ostial 194 (1
Restenotic 418 (2
Total occlusion 150 (9
Lesion characteristics, n (%)
Lesion length (mm) 15.2 11
Lesion type, n (%)
A, B1, B2 1,263 (7
C 343 (2
Vessels treated, n (%)
Left anterior descending 611 (3
Right coronary artery 466 (2
Circumflex 402 (2
Other 129 (8
Lesions per patient 1.6 0.
(n  80
Ejection fraction (%) 59.5 12
PCI  percutaneous coronary interventions; TVR  target v
of Cardiology/American Heart Association classification.ated by the nonsignificant Hosmer-Lemeshow test result Tp 0.1285). The mean area ( SD) under the ROC curve
f the bootstrap samples was 0.66 ( 0.03), indicating a fair
bility to discriminate between patients who required TVR
uring follow-up and those who did not.
alidation set. Results from fitting the same model used
or the whole (training) set to the subset with de novo
esions adjusted for intracoronary stents are displayed in
able 4. The predictors of ischemic TVR in this subgroup
ere similar to the overall group of patients treated for
schemic TVR. Area under the ROC curve for the predic-
ion model applied to the hold-out sample of 2,297 patients
as 0.64 (95% confidence interval 0.60 to 0.67), indicating
odest ability to discriminate in this subset of patients with
e novo lesions.
ISCUSSION
he present study demonstrated several clinical and angio-
raphic features that are associated with an increased risk of
d Without TVR
No TVR Event
(n  9,874) p Value
 0.001
3,052 (31)
5,670 (58)
1,063 (11)
87.2  10.4  0.001
5.2  9.8  0.001
9,784 (99) 0.49
321 (3)  0.001
7,947 (81)  0.001
848 (9) 0.50
966 (10) 0.010
1,540 (16) 0.79
8,643 (88)  0.001
1,929 (20)  0.001
2,598 (26) 0.013
4,777 (48) 0.67
931 (9)  0.001
3,038 (31)  0.001
652 (7)  0.001
1,229 (12)  0.001
867 (9) 0.47
13.3  8.5  0.001
 0.001
8,284 (84)
1,576 (16)
 0.001
3,629 (37)
3,309 (34)
2,387 (24)
549 (6)
1.4  0.7  0.001
(n  5,119)
60.3  12.4 0.07
vascularization; type A, B1, B2, and C  American Collegeth an
nt
9)
7)
7)
6)
8
.1
9)
)
0)
)
2)
6)
4)
5)
3)
8)
2)
6)
2)
6)
)
.0
9)
1)
8)
9)
5)
)
7
3)
.0VR after PCI. Younger age, hypertension, diabetes mel-
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linical variables associated with higher risk of ischemic
VR. Ostial lesion location, multivessel angioplasty, lesion
ocation in the left anterior descending artery, lesion length
ore than 20 mm, and use of rotablator were among the
esion- and procedure-related variables associated with isch-
mic TVR on follow-up. There was a significant increase in
he risk of ischemic TVR at U.S. treatment sites. Smoking
nd the use of stents were associated with a lower risk of
VR.
he present study. The target vessel (lesion) revascular-
zation rates have remained stable since the introduction of
ntracoronary stents. In the earlier Balloon-Expandable-
tent Implantation with Balloon Angioplasty in Patients
ith Coronary Artery Disease (Benestent) study, comparing
alloon angioplasty with intracoronary stents in patients
Table 3. Stepwise Multivariate Modeling Resu
PRESTO Trial*
Effect
Center: U.S. vs. other
Age (yrs)
Smoker
Hypertension
Diabetes: diet only or no treatment vs. no diabetes
Diabetes: insulin and/or oral agent vs. no diabetes
Diabetes: oral agent only vs. no diabetes
Prior coronary artery bypass surgery
Peripheral vascular disease
Current unstable angina
Lesion length: 20 mm vs. 20 mm
In-stent restenosis lesion
Ostial lesion
Stent
Vessel treated: LAD vs. other
Number of lesions treated: single vs. multiple
Rotablator
*Hosmer and Lemeshow Goodness of Fit test: chi-square 
0.1285.
CI  confidence interval; LAD  left anterior descendin
Its Outcomes trial.
Table 4. Stepwise Multivariable Modeling Res
Intracoronary Stents
Effect
Center: U.S. vs. other
Age
Smoker
Hypertension
Diabetes: diet only or no treatment vs. no diabetes
Diabetes: insulin and/or oral agent vs. no diabetes
Diabetes: oral agent only vs. no diabetes
Prior coronary artery bypass surgery
Peripheral vascular disease
Current unstable angina
Lesion length: 20 mm vs. 20 mm
Ostial lesion
Stent
Vessel treated: LAD vs. other
Number of lesions treated: single vs. multiple
RotablatorCI  confidence interval; LAD  left anterior descending artery.ith simple de novo lesions in the native coronary arteries,
he seven-month all-event rate in the stent arm was 13.5%
6). In a more recent higher-risk group of multivessel
isease in Arterial Revascularization Therapies Study
ARTS) group, the one-year repeat revascularization in the
tent-treated group was 16.8% (7). Similarly, in the
irolimus-Eluting Stents versus Standard-Stents in patients
ith in a native coronary artery (SIRIUS) trial, the target
esion revascularization at 270 days was 16.6% in the control
bare metal stent) group (8). In recent large pooled data
rom stent trials, the TVR rates were 14.3% in 6,186
atients (1). Despite worsening baseline and lesion charac-
eristics, the repeat revascularization rates have been the
ame and ranged between 13% and 16%. The ischemic
VR of 14% in the present study is similar to the previously
eported studies. The previously published data are, how-
Overall Patients Enrolled in
Odds Ratio 95% CI p Value
1.365 (1.190–1.566)  0.0001
0.987 (0.981–0.993)  0.0001
0.722 (0.611–0.853) 0.0001
1.232 (1.074–1.413) 0.0028
1.088 (0.850–1.392) 0.5029
1.530 (1.220–1.920) 0.0002
1.184 (1.184–1.425) 0.0748
1.393 (1.180–1.644)  0.0001
1.314 (1.035–1.667) 0.0249
1.446 (1.267–1.650)  0.0001
1.467 (1.233–1.745)  0.0001
2.050 (1.721–2.442)  0.0001
1.455 (1.185–1.787) 0.0003
0.840 (0.719–0.981) 0.0273
1.260 (1.059–1.374) 0.0047
0.580 (0.511–0.659)  0.0001
1.424 (1.097–1.848) 0.0079
456, degrees of freedom  8, probability  chi-square 
y; PRESTO  Prevention of Restenosis with Tranilast and
f De Novo Lesions Treated With
Odds Ratio 95% CI p Value
1.467 (1.259–1.709)  0.0001
0.989 (0.982–0.996) 0.0033
0.746 (0.620–0.897) 0.0018
1.225 (1.051–1.429) 0.0096
1.098 (0.833–1.448) 0.5059
1.421 (1.083–1.866) 0.0113
1.225 (0.991–1.515) 0.0612
1.301 (1.068–1.585) 0.0090
1.247 (0.941–1.653) 0.1247
1.389 (1.199–1.610)  0.0001
1.527 (1.246–1.872)  0.0001
1.339 (1.047–1.713) 0.0200
0.725 (0.603–0.872) 0.0006
1.313 (1.134–1.520) 0.0003
0.574 (0.498–0.663)  0.0001
1.436 (1.000–2.062) 0.0500lts of
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Restenosis Prediction After Coronary Angioplasty January 18, 2005:198–203ver, limited by single-center data, pooled data analysis from
everal registries and trials, or limiting the study to a specific
ubgroup. In a recent analysis of angiographic variables from
o Tirofiban and ReoPro Give Similar Efficacy Outcomes?
TARGET), the risk of six-month TVR was independently
ssociated with left anterior descending coronary artery
esions (hazard ratio 1.46; p  0.001), restenotic lesions at
aseline (hazard ratio 1.58; p  0.006), and lesion length
hazard ratio 1.19; p  0.03) (9). In the Enhanced Sup-
ression of the Platelet IIb/IIIa Receptor with Integrilin
herapy (ESPRIT) trial, the triple composite of death,
yocardial infarction, or TVR at 12 months was reduced
rom 22.1% in the placebo-treated patients to 17.5% with
ptifibatide treatment (hazard ratio 0.76; 95% confidence
nterval 0.63 to 0.93; p  0.007). Overall rates for TVR
ere greater in patients with diabetes (hazard ratio 1.59;
5% confidence interval 1.21 to 2.08; p  0.001) (10).
In contrast, the data of this retrospective analysis were
erived from a single, largest, prospective, multicenter,
ultinational trial with same primary end point (silent and
ymptomatic) TVR on follow-up. The patient population
ncluded lesion characteristics and the treatment offered;
hey are representative of current interventional practice and
epresent the “real-world” TVR rates.
The variables identified in the present study associated
ith increased risk for ischemic TVR have previously been
eported with the notable addition of higher incidence of
schemic TVR in patients treated in the U.S. compared with
atients treated in the other countries. The reason for
igher ischemic TVR is not exactly known; however, higher
revalence of adverse baseline characteristics associated with
estenosis, more aggressive invasive approach to patients’
ymptoms (11,12), abnormalities noted in the stress test, or
ome unidentified factors in the U.S. population that can
ncrease the restenosis and, consequently, the TVR could be
he possible factors.
redictors of ischemic TVR. As previously mentioned,
he predictors of ischemic TVR were, in general, similar to
estenosis (3,13–15). We did a subset analysis on patients
ith de novo lesions that received stents to analyze the
redictors of ischemic TVR in a uniform population. The
redictors identified in this subgroup were essentially similar
o the overall population. However, the predictive accuracy
f the models derived from PRESTO data, to differentiate
etween patients who would and who would not develop
schemic TVR, was modest. These data are in line with the
reviously published studies with low-to-modest predictive
ccuracy for prediction of restenosis and TVR (3,15,16).
arget vessel size was not included as a predictor, as it was
nly available in the angiographic substudy of the trial.
espite inclusion of all the clinical, lesion-specific, and
rocedural variables, there may be some unmeasured pa-
ient, genetic, or lesion-specific variables that can account
or the remainder (17–20). Until these unmeasured con-
ounders are known, we may not be able to accurately
redict the likelihood of a patient developing restenosis (andschemic TVR) after successful percutaneous revasculariza-
ion. It would also be difficult to develop treatment algo-
ithms (including drug-eluting stents) based on the available
linical, angiographic, and procedural data.
tudy limitations. This large prospective study lacked the
redictive accuracy to differentiate patients who needed
VR from a group that did not. Though this study is one of
he largest and representative of the recent practice, many
mportant subsets, namely vein grafts, bifurcation, left main
isease that are known to have higher restenosis, were
nderrepresented. Also, other features believed to be asso-
iated with higher risk of repeat revascularization (e.g.,
hronic total occlusion, and patients with chronic renal
ailure) were underrepresented. Thus, these features could
ot be evaluated in the present study. The PRESTO trial
id not include patients who received intracoronary brachy-
herapy or drug-eluting stents and, therefore, our analysis
annot be extrapolated to this subset. The predictors for
VR had only modest discriminatory accuracy with a
-statistic of 0.66. It is likely that some unmeasured vari-
bles are affecting restenosis and, consequently, repeat
evascularization.
onclusions. The TVR of 14% found in this study is
epresentative of the “real-world” repeat revascularization
ates with current patient demographics, lesion characteris-
ics, and procedural techniques. These rates may serve as
enchmark to compare the effect of newer strategies to
educe restenosis and TVR. The predictive accuracy of
linical and angiographic variables in TVR prediction is
odest, and should serve as an impetus to search for newer
arkers for restenosis prediction.
eprint requests and correspondence: Dr. David R. Holmes, Jr.,
ivision of Cardiovascular Diseases, Department of Internal Medi-
ine, Mayo Clinic, 200, 2nd Street SW, Rochester, Minnesota 55905.
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